In addition, the newly appointed Advisory Board Member, Dr. Hui, reported that his representation of the Company at the 2018 Asia -Pacific Precision Medicine Forum was successfully received by the many of the Pharmaceutical and Medical professionals attending the Symposium.
Dr. Hui is an expert on metabolic diseases, oncology and wellness. He also serves as an active consultant for government and industry in medical and biotechnological areas. He is the author of over 150 scientific papers and dozen patents on metabolic and cancer studies. He is an associate editor of “Pancreas” and “Frontier in Gastrointestinal Science”, and serves as editor board on 8 professional journals.
“The Company continues to make strides in its efforts to bring its Immunotherapy to Market in Eastern Europe and is pleased with the first steps it has taken in exploring the receptiveness to its technology in Asia,” stated Harry Zhabilov, CEO.